Integrated MRI and blood markers to predict radiation failures in brain metastases from NSCLC
Official title: Integrated MRI and blood biomarkers to predict radiation failure patterns and survival in brain metastases from non-small cell lung cancer
Funded at Wake Forest University Health Sciences · NIH-11374199 · Data updated 2026-11-12
Aims to build a person-friendly model using MRI scans and blood biomarkers to predict how brain metastases from non-small cell lung cancer will respond to radiation therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $228,195 |
| NIH project number | 1R21EB037713-01A1 |
| Project ID | NIH-11374199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with non-small cell lung cancer who have brain metastases and are undergoing radiotherapy.
✕Less likely to help
Patients without brain metastases or those not considered for radiotherapy may not benefit.
What this research studies
This project will combine pre-treatment MRI data, blood biomarker information, and clinical markers to forecast where and when radiation therapy might fail in brain metastases from NSCLC. A multitask deep learning model will be developed and validated to predict radiation failure patterns and long-term survival. The goal is to tailor treatment plans early so clinicians can intervene sooner and improve quality of life and outcomes for patients.
Why it matters
Potential benefit: If successful, the approach could help clinicians personalize radiation strategies for NSCLC brain metastases, potentially reducing treatment failure and improving survival.
How similar studies have gone: Prior studies show promise for MRI and biomarker-based predictions, but this project aims to advance through a multimodal deep learning approach.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Jiang, Yuming — Wake Forest University Health Sciences
- Study coordinator: Jiang, Yuming
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.